FIRST MANHATTAN CO. LLC. - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 35 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
FIRST MANHATTAN CO. LLC. ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q2 2022$1,0000.0%5000.0%0.00%
Q1 2022$1,000
-50.0%
5000.0%0.00%
Q4 2021$2,000
+100.0%
5000.0%0.00%
Q3 2021$1,0000.0%5000.0%0.00%
Q2 2021$1,0000.0%5000.0%0.00%
Q1 2021$1,000
-50.0%
5000.0%0.00%
Q4 2020$2,000
-97.0%
500
-87.5%
0.00%
Q3 2020$67,000
+52.3%
4,0000.0%0.00%
Q2 2020$44,000
+144.4%
4,0000.0%0.00%
Q1 2020$18,000
+5.9%
4,0000.0%0.00%
Q4 2019$17,000
+13.3%
4,0000.0%0.00%
Q3 2019$15,000
+15.4%
4,000
+14.3%
0.00%
Q2 2019$13,000
-13.3%
3,5000.0%0.00%
Q1 2019$15,000
+25.0%
3,5000.0%0.00%
Q4 2018$12,000
-7.7%
3,5000.0%0.00%
Q3 2018$13,0000.0%3,5000.0%0.00%
Q2 2018$13,000
+18.2%
3,5000.0%0.00%
Q1 2018$11,000
-15.4%
3,5000.0%0.00%
Q4 2017$13,000
-7.1%
3,5000.0%0.00%
Q3 2017$14,0003,5000.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q1 2018
NameSharesValueWeighting ↓
SABBY MANAGEMENT, LLC 242,850$923,0000.13%
ABNER HERRMAN & BROCK LLC 241,500$918,0000.13%
Weaver Consulting Group 48,881$186,0000.10%
Tibra Equities Europe Ltd 87,000$331,0000.10%
Ikarian Capital, LLC 293,200$1,115,0000.09%
GSA CAPITAL PARTNERS LLP 60,238$229,0000.03%
Ergoteles LLC 124,329$472,0000.01%
CFO4Life Group, LLC 12,003$46,0000.01%
HighPoint Advisor Group LLC 17,033$65,0000.01%
BOOTHBAY FUND MANAGEMENT, LLC 32,836$125,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders